title: Synchronous antiresorptive osteonecrosis of the jaws and breast cancer metastasis.
abstract: Antiresorptive osteonecrosis of the jaws (ARONJ) is a significant and poorly understood oral complication that may affect patients receiving antiresorptive agents, such as intravenous bisphosphonate therapy. There are scarce reports of the coexistence of ARONJ and metastasis at the same jaw site in the English-language literature. In the present case, a 60-year-old white woman was referred for the evaluation of a nonhealing extraction socket. The patient was undergoing treatment with intravenous zoledronic acid to metastatic breast cancer in bone, and her medical history and clinical characteristics led to the diagnosis of ARONJ. Nevertheless, histologic analysis showed a fragment of necrotic bone and bacterial colonies associated with malignant epithelial cells that were confirmed to be metastatic breast adenocarcinoma. This case showed that jaw metastasis can occur at the same time and site of ARONJ, making diagnosis and management challenging.
authors: Piracicaba Dental School, State University of Campinas (UNICAMP), Piracicaba, São Paulo, Brazil.
authors: Isadora Luana
authors: IL
authors: Flores
authors: Piracicaba Dental School, State University of Campinas (UNICAMP), Piracicaba, São Paulo, Brazil.
authors: Alan Roger
authors: AR
authors: dos Santos-Silva
authors: Piracicaba Dental School, State University of Campinas (UNICAMP), Piracicaba, São Paulo, Brazil.
authors: Ricardo
authors: R
authors: Della Coletta
authors: Piracicaba Dental School, State University of Campinas (UNICAMP), Piracicaba, São Paulo, Brazil.
authors: Pablo Agustin
authors: PA
authors: Vargas
authors: Piracicaba Dental School, State University of Campinas (UNICAMP), Piracicaba, São Paulo, Brazil. Electronic address: malopes@fop.unicamp.br.
authors: Márcio Ajudarte
authors: MA
authors: Lopes
mesh_terms: D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000150:complications*; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D001859:Bone Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000473:pathology*; D003952:Diagnostic Imaging; D004164:Diphosphonates / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects*; D008175:Lung Neoplasms / Q000556:secondary; D008441:Maxillary Neoplasms / Q000556:secondary*; D008875:Middle Aged; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid